Posts

Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, the Denmark-based biotech company’s COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTech’s mRNA-based vaccine.

On Friday, the World Trade Organization approved vaccine patent waivers to increase the availability of COVID-19 vaccines to lower-income countries.

Advisers to the U.S Food and Drug Administration on Wednesday unanimously recommended the agency authorize COVID-19 vaccines from Moderna Inc. and Pfizer Inc./BioNTech SE for millions of the youngest American children.

Although a handful of companies have dominated the COVID-19 vaccine market in the U.S. and Europe — Pfizer-BioNTech, Moderna, Johnson & Johnson, AstraZeneca-Oxford — a number of companies are continuing to develop vaccines in hopes they can be used as booster shots. 

U.S. Food and Drug Administration staff reviewers on Sunday said Pfizer-BioNTech’s COVID-19 vaccines were effective and safe for use in children aged 6 months to 4 years.

Pre-orders of vaccines for children under age five have been slow, but Biden administration senior officials say they are not alarmed and expect the pace to pick up after federal approvals later this month.

A look at some of the latest COVID-19 news includes the U.S. Food and Drug Administration’s plans to review changes to Novavax’s manufacturing process before the regulatory agency authorizes the company’s vaccine. Moderna expects to submit data to regulators soon with expectations of the company’s bivalent COVID-19 vaccine—consisting of the original Spikevax vaccine and a newer version, mRNA-1273.214 that contains an Omicron-specific vaccine—becoming available in late summer.

Moderna Inc. said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

Advisers to the U.S. Food and Drug Administration on Tuesday voted overwhelmingly to recommend that the regulatory agency authorize Novavax Inc.’s COVID-19 vaccine for use in adults, which the drugmaker hopes can become the shot of choice among some American vaccine skeptics.

Johnson & Johnson and Emergent BioSolutions are accusing each other of breaching their COVID-19 vaccine supply agreement.